A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

Key facts

Study ID

NCT06318676

Run by

Celgene

People needed

26

Starts

2024-03-21

Expected to finish

2024-11-15

Last updated by the study team

2025-06-04

Who can join

Age: 18 and older, up to 82. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must have a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 40.0 kg/m2 inclusive at screening.
• Participants must have a body weight ≥ 50 kg at screening.
• Participants must be afebrile (febrile is defined as ≥ 38°C or 100.4°F) at screening, check in, and predose.

You may not qualify if…

• Participants must not have any history of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide.
• Participants must not have any history of malignancy of any type other than in situ cervical cancer or surgically excised non-melanomatous skin cancers.
• Participants with an inability to tolerate oral medication.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• PANAX — Miami Lakes, Florida, United States
• Omega Research Group - Orlando — Orlando, Florida, United States
• Orlando Clinical Research Center OCRC — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.